324 related articles for article (PubMed ID: 35484511)
1. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
Li J; Wang J; Ding Y; Zhao J; Wang W
BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
[TBL] [Abstract][Full Text] [Related]
2. Establishment and validation of a novel prognostic model for lower-grade glioma based on senescence-related genes.
Li J; Wang J; Liu D; Tao C; Zhao J; Wang W
Front Immunol; 2022; 13():1018942. PubMed ID: 36341390
[TBL] [Abstract][Full Text] [Related]
3. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
4. Prognostic biomarker CCR6 and its correlation with immune infiltration in cutaneous melanoma.
Nurzat Y; Dai D; Hu J; Zhang F; Lin Z; Huang Y; Gang L; Ji H; Zhang X
Front Oncol; 2023; 13():1162406. PubMed ID: 37182147
[TBL] [Abstract][Full Text] [Related]
5. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
7. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
Tan S; Spear R; Zhao J; Sun X; Wang P
Front Genet; 2022; 13():905047. PubMed ID: 35832194
[TBL] [Abstract][Full Text] [Related]
9. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
10. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
12. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway.
Su X; Liu J; Tu Z; Ji Q; Li J; Liu F
Transl Cancer Res; 2024 Apr; 13(4):1786-1806. PubMed ID: 38737693
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of lysyl oxidase is associated with poor prognosis and response to therapy of patients with lower grade gliomas.
Huang SP; Chiou J; Jan YH; Lai TC; Yu YL; Hsiao M; Lin YF
Biochem Biophys Res Commun; 2018 Jun; 501(3):619-627. PubMed ID: 29729273
[TBL] [Abstract][Full Text] [Related]
15. A Risk Score Signature Consisting of Six Immune Genes Predicts Overall Survival in Patients with Lower-Grade Gliomas.
Wu Y; Peng Z; Gu S; Wang H; Xiang W
Comput Math Methods Med; 2022; 2022():2558548. PubMed ID: 35186111
[TBL] [Abstract][Full Text] [Related]
16. Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma.
Wang LC; Cui WY; Zhang Z; Tan ZL; Lv QL; Chen SH; Shen XL
Brain Res Bull; 2021 Oct; 175():26-36. PubMed ID: 34280481
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
Front Oncol; 2020; 10():1409. PubMed ID: 32974146
[TBL] [Abstract][Full Text] [Related]
18. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma.
Ma W; Mei P
World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196
[TBL] [Abstract][Full Text] [Related]
19. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
20. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
Front Genet; 2021; 12():718717. PubMed ID: 34925438
[No Abstract] [Full Text] [Related]
[Next] [New Search]
